CN101254209A - Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof - Google Patents

Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof Download PDF

Info

Publication number
CN101254209A
CN101254209A CNA2008100505392A CN200810050539A CN101254209A CN 101254209 A CN101254209 A CN 101254209A CN A2008100505392 A CNA2008100505392 A CN A2008100505392A CN 200810050539 A CN200810050539 A CN 200810050539A CN 101254209 A CN101254209 A CN 101254209A
Authority
CN
China
Prior art keywords
calf spleen
spleen extract
solution
column chromatography
extract solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008100505392A
Other languages
Chinese (zh)
Other versions
CN101254209B (en
Inventor
滕利荣
田晓乐
张志文
孟庆繁
逯家辉
袁利佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JILIN AODONG ZHAONAN PHARMACEUTICAL CO Ltd
Original Assignee
JILIN AODONG ZHAONAN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JILIN AODONG ZHAONAN PHARMACEUTICAL CO Ltd filed Critical JILIN AODONG ZHAONAN PHARMACEUTICAL CO Ltd
Priority to CN2008100505392A priority Critical patent/CN101254209B/en
Publication of CN101254209A publication Critical patent/CN101254209A/en
Application granted granted Critical
Publication of CN101254209B publication Critical patent/CN101254209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a calf spleen extract injection prepared by reversed-phase column chromatography and a preparation method thereof. The original calf spleen extract solution is purified by reversed-phase column chromatography with simple process, so as to remarkably improve the stability of product and the quality standard of pharmacologically active substance. The inventive method utilizes the reversed-phase column chromatography instead of conventional adsorption, elution and ion-exchange column chromatography, so as to reduce production process and meet the requirement of improving product quality standard. Compared with the prior calf spleen extract solution, the inventive product has the advantages of low toxic and side effects and low content of pigment impurities. The No.7 peak area in HPLC chromatogram is improved from 17.66% before reversed-phase chromatography to 51.82% after reversed-phase chromatography, thus indicating high unit content of effective component.

Description

Calf spleen extract injection prepared by inphase opposition column chromatography and preparation method
Technical field
The present invention relates to the production technology of calf spleen extract injection, a kind of calf spleen extract injection prepared by inphase opposition column chromatography and preparation method especially are provided, belong to biological pharmacy technical field.
Background technology
Many studies confirm that extensively exists low molecule tumour-inhibitory substance in biological intravital multiple histiocyte and the body fluid, may be the intermediate product of the specific synthetic or substance metabolism of histiocyte.Its structure and physicochemical property differ, but remove malignant conversioning cell in vivo, prevent that tumor from taking place to play an important role in the process with development.
Bibliographical information, the polypeptides matter that extracts from Lien Sus domestica have natural biological and learn actively, not only can suppress growth of tumor, still can stimulating immune system, and impel interferon to discharge, increase the T cytoactive, globality ground human body immunity improving ability and anti-cancer ability.Domestic research to the spleen peptide at present is less, and it is raw material with the Lien Bovis seu Bubali that bibliographical information is arranged, and adopts ultrafiltration and centrifugation technique to prepare the low molecule tumour-inhibitory substance of spleen.
Calf spleen extract injection can be used for human body immunity improving power, obviously improves the leukocyte number.Leukopenia, the various malignant tumor that can cause at treatment aplastic anemia, essential thrombocytopenia, lonizing radiation, be used when improving the tumor patient dyscrasia.Yet the calf spleen extract injection product impurity that existing market is sold is more, the time have anaphylaxis to take place, and pharmacologically active instability has influenced the use curative effect of this medicine.
Summary of the invention
The invention provides a kind of calf spleen extract injection, leukogenic effect is apparently higher than existing product.
The invention also discloses the preparation method of calf spleen extract injection, former calf spleen extract solution is carried out the reversed phase column chromatography purification, purifying process is easy, obviously improves the quality standard of product stability and pharmacologically active.
Calf spleen extract solution of the present invention is characterized in that:
Be faint yellow settled solution; PH value is 5.0~7.0; Molecular weight 4000-6000 dalton;
Add water and make the solution that contains polypeptide 20ug among every 1ml,, absorption maximum is arranged at the wavelength place of 194nm according to spectrophotometry;
Protein: calf spleen extract solution 2.0ml, add 20% sulfosalicylic acid solution 2.0ml, muddiness must not take place in mixing;
Trap: calf spleen extract solution adds water and makes the solution that contains polypeptide 20ug among every 1ml, should be 2.0~2.5 at the ratio of 260nm and 280nm wavelength place trap.
The preparation method of calf spleen extract solution of the present invention may further comprise the steps:
1, gets calf spleen extract injection 200ml, be splined on the anion-exchange chromatography post and carry out reversed phase chromatography (comprising the DEAE cellulose, anionites such as macroreticular weakly base acrylic acid type anion exchange resin);
2, balance liquid is the phosphate buffer of 5~20mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.
Best process flow is as follows:
1, gets calf spleen extract injection 200ml, be splined on 400ml macroreticular weakly base acrylic acid type anion exchange resin chromatographic column and carry out reversed phase chromatography;
2, balance liquid is the phosphate buffer of 10mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.
Good effect of the present invention is: broken conventional absorption, eluting ion-exchange chromatography method, adopted reversed phase ion displacement chromatography method, reduced the technological process of production, reached the requirement of the standard of improving the quality of products; Product of the present invention is compared with former Calf Spleen extracting solution has that toxic and side effects is little, pigment impurity content is low, and impurity content reduces, thereby toxic and side effects is reduced.No. 7 peak area percentage ratios of high performance liquid chromatography 17.66% before by reversed phase chromatography brought up to 51.82% behind the chromatography, unit active constituent content height.
Experimental example 1
Refining calf spleen extract injection vigor pharmacological evaluation
Adopt numeration of leukocyte to investigate the function of increasing leukocyte of this Calf Spleen refined liquid
1.1 vitality test
This product is added water make the solution that contains polypeptide 2.5mg among every 1ml, as need testing solution.Select 3 of the healthy rabbits of 2~3kg, check before the injection and then carry out intramuscular injection by leukocyte count, dosage was checked leukocyte count by rabbit body weight 1kg intramuscular injection need testing solution 1ml in back 24 hours in injection.
1.3 experimental result
1.3.1 this refining calf spleen extract injection (peptide concentration is 2.5mg/ml), by after the body weight administration, the leukocyte number on average raises 1.36 times before and after the injection
1.3.2 experimental data table
Administered intramuscular is investigated this refined soln and is risen white effect and refining preceding contrast.
Figure A20081005053900051
Contrast with blank group before the injection: * * * *P<0.000001.Referring to Fig. 1, Fig. 2.
Description of drawings
Fig. 1 analyses preceding high-efficient liquid phase chromatogram for the calf spleen extract injection anion exchange resin layer;
Fig. 2 analyses the back high-efficient liquid phase chromatogram for the calf spleen extract injection anion exchange resin layer.
The specific embodiment
The present invention is raw material with the calf spleen extract injection, and concrete implementation step is as follows, but and does not mean that limitation of the scope of the invention.
Embodiment 1
1, gets calf spleen extract injection 200ml, be splined on the anion-exchange chromatography post and carry out reversed phase chromatography (DEAE cellulose);
2, balance liquid is the phosphate buffer of 5~20mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.
Embodiment 2
1, gets calf spleen extract injection 200ml, be splined on 400ml macroreticular weakly base acrylic acid type anion exchange resin chromatographic column (D311) and carry out reversed phase chromatography;
2, balance liquid is the phosphate buffer of 10mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.See Fig. 2.
Embodiment 3
1, gets calf spleen extract injection 100ml, be splined on 250ml 330 alkalescence epoxy type anion exchange resin chromatographic columns;
2, balance liquid is the phosphate buffer of 5~20mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.See Fig. 2.
Embodiment 4
1, gets calf spleen extract injection 200ml, be splined on 400ml macroreticular weakly base acrylic acid type anion exchange resin chromatographic column (DE51, DE52, DE53, QA52) and carry out reversed phase chromatography;
2, balance liquid is the water buffer of the concrete pH6.3 in 10mmol/ml, pH5~7;
3, collect vigor peak with function of increasing leukocyte.See Fig. 2.

Claims (4)

1, a kind of calf spleen extract solution is characterized in that:
Be faint yellow settled solution; PH value is 5.0~7.0; Molecular weight 4000-6000 dalton;
Add water and make the solution that contains polypeptide 20ug among every 1ml,, absorption maximum is arranged at the wavelength place of 194nm according to spectrophotometry;
Protein: calf spleen extract solution 2.0ml, add 20% sulfosalicylic acid solution 2.0ml, muddiness must not take place in mixing;
Trap: calf spleen extract solution adds water and makes the solution that contains polypeptide 20ug among every 1ml, should be 2.0~2.5 at the ratio of 260nm and 280nm wavelength place trap.
2, the preparation method of calf spleen extract solution according to claim 1 is characterized in that with the Calf Spleen being the aqueous solution that raw material makes, through anti-phase anion exchange resin layer analyse, the technical process of distilling under reduced pressure, step is as follows:
Said anion exchange resin layer is analysed and is, water extract is analysed post through anion exchange resin layer; Balance liquid is the phosphate buffer or the distilled water of 5~20mmol/ml, pH5~7, collects the vigor peak with function of increasing leukocyte;
Described anionite: be selected from DEAE cellulose, the macroreticular weakly base acrylic acid type anion exchange resin etc. any one.
3, the described calf spleen extract solution of claim 1 improves the application of exempting from the body epidemic disease power medicine in preparation.
4, the application of the leukopenia that causes at preparation treatment aplastic anemia, essential thrombocytopenia, lonizing radiation of the described calf spleen extract solution of claim 1, various malignant tumor, disease medicament.
CN2008100505392A 2008-03-26 2008-03-26 Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof Active CN101254209B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008100505392A CN101254209B (en) 2008-03-26 2008-03-26 Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008100505392A CN101254209B (en) 2008-03-26 2008-03-26 Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof

Publications (2)

Publication Number Publication Date
CN101254209A true CN101254209A (en) 2008-09-03
CN101254209B CN101254209B (en) 2011-02-16

Family

ID=39889533

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008100505392A Active CN101254209B (en) 2008-03-26 2008-03-26 Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof

Country Status (1)

Country Link
CN (1) CN101254209B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108129549A (en) * 2017-12-19 2018-06-08 浙江丰安生物制药有限公司 The extracting method of polypeptide in a kind of spleen aminopeptide
CN108148111A (en) * 2017-12-19 2018-06-12 浙江丰安生物制药有限公司 The extracting method of polypeptide in a kind of spleen aminopeptide
CN113975296A (en) * 2021-12-30 2022-01-28 北京第一生物化学药业有限公司 Application of animal spleen extract in preparation of medicine for treating Alzheimer's disease
CN114940698A (en) * 2022-07-22 2022-08-26 北京第一生物化学药业有限公司 Method for extracting acidic polypeptide from spleen aminopeptide stock solution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1253008A (en) * 1998-10-30 2000-05-17 任天保 Osteophyte pill and osteophyte-eliminating ointment for treating hyperosteogeny

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108129549A (en) * 2017-12-19 2018-06-08 浙江丰安生物制药有限公司 The extracting method of polypeptide in a kind of spleen aminopeptide
CN108148111A (en) * 2017-12-19 2018-06-12 浙江丰安生物制药有限公司 The extracting method of polypeptide in a kind of spleen aminopeptide
CN108129549B (en) * 2017-12-19 2020-06-05 浙江丰安生物制药有限公司 Method for extracting polypeptide in spleen aminopeptide
CN108148111B (en) * 2017-12-19 2020-06-05 浙江丰安生物制药有限公司 Method for extracting polypeptide in spleen aminopeptide
CN113975296A (en) * 2021-12-30 2022-01-28 北京第一生物化学药业有限公司 Application of animal spleen extract in preparation of medicine for treating Alzheimer's disease
CN113975296B (en) * 2021-12-30 2022-04-12 北京第一生物化学药业有限公司 Application of animal spleen extract in preparation of medicine for treating Alzheimer's disease
CN114940698A (en) * 2022-07-22 2022-08-26 北京第一生物化学药业有限公司 Method for extracting acidic polypeptide from spleen aminopeptide stock solution

Also Published As

Publication number Publication date
CN101254209B (en) 2011-02-16

Similar Documents

Publication Publication Date Title
CN103340983B (en) Lycium ruthenicum fruit extract as well as preparation method and application thereof
CN101254209B (en) Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof
CN109010618B (en) Traditional Chinese medicine composition with anti-tumor effect and preparation method and application thereof
CN105148258A (en) Composition and application thereof, and preparation containing composition
CN102772500A (en) Relingqing Polygonum capitatum Buch-Ham ex D.Don raw material extract with anti-inflammatory action
CN102875689A (en) Preparation method and application of ophiopogon japonicus polysaccharide
CN101306077B (en) Chinese traditional injection preparation for treating cancer and its preparation method
CN101381408B (en) Cobratide extraction method, cobratide extracted thereby and formulation containing cobratide
CN103705754A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus
CN1265911A (en) Medicine for treating cardiovascular disease and preparation process thereof
CN102805767A (en) Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect
CN101455844B (en) PEG-erythrocyte-stimulating factor and preparation method and use thereof
CN1205216C (en) Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage
CN100427140C (en) Freeze-drying powder injection of Bozhi glycopeptide and its preparation
CN102846704B (en) A Leonurus japonicus injection, its preparation method, and method for detecting total alkaloids
CN1883566A (en) Anti-inflammation medicine and method for preparing same
CN103550237B (en) Composition of active ingredients of rubia cordifolia as well as application of composition in medicines
CN101618069B (en) Capsule preparation for treating bruise as well as bleeding and easing pain and preparation method and use thereof
CN102145040A (en) Technique for adsorbing and extracting effective part of folium orthosiphoni by employing macroporous resin
CN101396373A (en) Cinobufacini extract and preparation method thereof
CN101084979A (en) Medicinal preparation for cancer auxiliary treatment and its preparation method
CN1264530C (en) Freeze-dried 'Shenqifuzheng' powder for injection and its preparing process
CN100528175C (en) Deporteinnized calf serum injection and its preparing method
CN102993267A (en) Preparation method of glossy ganoderma bioactive peptide
CN100391533C (en) Wood louse analgesia peptide, preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant